Point72 Asset Management
IBRX icon

Point72 Asset Management’s ImmunityBio IBRX Stock Holding History

Point72 Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,500
Closed -$26.2K – 2431
2023
Q3 		$26.2K Buy
+15,500
New +$31.1K ﹤0.01% 2258
2023
Q2 		– Sell
-106,340
Closed -$194K – 2443
2023
Q1 		$194K Buy
+106,340
New +$331K ﹤0.01% 1493

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Point72 Asset Management's IBRX Position: Q4 2023 in Review

Point72 Asset Management sold out of ImmunityBio (IBRX) in Q4 2023, closing a stake of 15,500 shares — an estimated $26.2K sold.

Point72 Asset Management first reported a position in IBRX in Q1 2023 and held it in 2 quarters. The position peaked at $194K in Q1 2023. 147 funds tracked by Wall St. Rank hold IBRX as of Q4 2023.

  • Point72 Asset Management reported no remaining ImmunityBio position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 15,500 ImmunityBio shares in Q4 2023, an estimated $26.2K.
  • Point72 Asset Management first reported a position in ImmunityBio in Q1 2023 and held it in 2 quarters.
  • Point72 Asset Management's ImmunityBio position peaked at $194K in Q1 2023.
  • 147 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.